Laurus Labs Share Price Dips Over 3% Amid Q2 Profit Booking | Stock Market Today

The shares of Laurus Labs witnessed a sharp movement on October 24, reflecting investor caution despite impressive quarterly results. After touching a near all-time high in early trade, the stock experienced a notable decline as profit booking entered the market.

Market Performance

• Laurus Labs opened higher at around Rs 943 per share, approaching its all-time peak of Rs 944.
• However, profit booking weighed on the stock, dragging it down by over 3.4% to Rs 902.35 during mid-morning trading.
• The movement highlights typical investor behavior after a strong quarterly performance, where gains are partially realized in the short term.

Laurus Labs Q2 FY26 Results

Laurus Labs released its July-September quarter (Q2 FY26) results on October 23, reporting impressive growth across key financial metrics:

• Net Profit: Rs 195 crore, up 875% YoY from Rs 19.84 crore in Q2 FY25.
• Revenue from Operations: Rs 1,653.47 crore, up 35% YoY from Rs 1,223.70 crore.
• EBITDA: Rs 429 crore, rising 136% YoY; EBITDA margin expanded to 26% from 14.9% in the same period last year.

Segment-wise Performance

• CDMO (Contract Development & Manufacturing Organization) Revenue: Rs 518 crore, up 53% YoY, driven by late-phase and commercial deliveries in small molecules.
• Generics Revenue: Rs 1,135 crore, up 28% YoY, supported by higher ARV volumes and supplies to developed markets.

These figures show Laurus Labs’ robust growth across both CDMO and generics segments, signaling consistent operational performance even amid broader market volatility.

Company Overview

Laurus Labs has carved a strong niche in pharmaceuticals with a focus on:

• Active pharmaceutical ingredients (APIs) and generic drugs
• Contract development and manufacturing services for global clients
• Developed market penetration, particularly in ARV and small molecule drugs

The company’s performance reflects both strategic execution and demand momentum across its portfolio.

Summary

Even though the stock saw a 3% dip on October 24, the strong Q2 results highlight Laurus Labs’ steady growth trajectory:

• Revenue and net profits saw significant YoY improvements.
• EBITDA margins doubled, reflecting operational efficiency.
• CDMO and generics segments contributed to balanced growth.

Investors following stock market today trends witnessed the typical post-earnings profit booking, despite the company’s solid financials.

Bottom line: Laurus Labs continues to show healthy financial performance, with strong revenue and profitability growth, while stock market movements reflect short-term investor adjustments rather than long-term concerns.